Lidia Klyukina

Mrs. Lidia Klyukina


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2022 in Obstetrics, Gynecology and Reproduction
Verified
Journal Article
Open access
PDF file
IRI. V. Reshetov
I. V. Reshetov
ESE. A. Sosnova
E. A. Sosnova
AUA. L. Unanyan
A. L. Unanyan
AIA. A. Ishchenko
A. A. Ishchenko
LKLidia Klyukina
Lidia Klyukina
Photodynamic therapy and cervical intraepithelial neoplasia: current achievements and development prospects

29 July 2024 in Tumors of female reproductive system
Verified
Journal Article
Open access
PDF file
LKLidia Klyukina
Lidia Klyukina
ESE. A. Sosnova
E. A. Sosnova
AIA. A. Ishchenko
A. A. Ishchenko
MDM. M. Davydov
M. M. Davydov
Background. Cervical cancer (CC) refers to cancer of visual localization and in women of reproductive age remains one of the most common oncological diseases. The carcinogenesis of CC is caused by the persistence of highly oncogenic types of human papillomavirus (HPV), the level of carcinogenicity of which is the highest based on the criteria of the International Agency for Research on Cancer. However, cervical carcinogenesis does not occur in all cases of persistence of highly oncogenic types of HPV. This, in turn, determines the need for a thorough search, study and analysis of possible cofactors that can lead to neoplastic changes in the cervix.Aim. To develop a model for predicting the individual risk of CC in women of reproductive age, taking into account clinical, anamnestic, laboratory and histological data.Materials and methods. The material for the study was retrospective examination data from 251 patients of reproductive age who were treated at the Center for Gynecology and Reproductive Technologies of the National Medical Research Center “Medical and Rehabilitation Center”, Ministry of Health of Russia in the period 2015–2022. Results. Highly oncogenic HPV types were significantly more common in the group of patients with verified СС who took combined oral contraceptives (COC), compared with patients who did not take COC (p = 0.035). Multifactorial analysis allowed us to determine that long-term use of СОС for a total of more than 7 years is associated with a tendency to increase the risk of developing СС (hazard ratio 1.68; 95 % confidence interval 1.1–2.5; p = 0.010). According to the results of statistical calculation, the values of regression coefficients were obtained and the tendency to increase the risk of developing CC was predicted in the presence of such factors as: HPV type 16 persistence, body mass index, and the duration of COC intake in years.Conclusion. Thus, taking into account all possible risk factors for CC, the negative effect of cofactors, namely increased body mass index and prolonged intake of COC, on the course of HPV as the leading etiological factor of breast cancer, will allow us to identify groups at increased risk of developing CC, form an individual algorithm for monitoring and examination throughout the entire period of taking COC, as well as conduct individual cancer prevention by limiting the duration of taking COC.

16 June 2023 in V.F.Snegirev Archives of Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
LKLidia Klyukina
Lidia Klyukina
ESElena A. Sosnova
Elena A. Sosnova
AIAnton A. Ishchenko
Anton A. Ishchenko
MDMikhail M. Davydov
Mikhail M. Davydov
КАКлюкина Лидия Александровна
Клюкина Лидия Александровна
BACKGROUND: Cervical cancer is one of the leading cancers in women of reproductive age. The etiological role of the human papillomavirus (HPV) in cancer development is long known and undisputed. However, owing to the widespread use of combined oral contraceptives (COCs), scientists actively investigate possible mechanisms of interrelation between sex steroids and HPV in terms of cervical cancer risk. AIM: This study aimed to assess the risk of cervical cancer in women of reproductive age, depending on the use of COCs for different durations. MATERIALS AND METHODS: The study included 411 patients of reproductive age who were treated at the Center for Gynecology and Reproductive Technologies of the Russian Ministry of Health and the Department of Oncogynecology at the University Clinical Hospital No. 4 of the I.M. Sechenov First Moscow State Medical University between January 2015 and December 2021. All patients were divided into two groups. The study group included 291 patients with verified cervical cancer, and the control group included 120 patients without cancer. RESULTS: The study group was significantly more likely to take COCs (56, or 19.2%) than the control group (11, or 6.5%; p=0.018). In addition, the study group had significantly longer treatment durations (p=0.011). Overweight (n = 52, or 17.9%) and grade II obesity (n = 11, or 3.8%, vs. 0; p=0.03) were significantly more common in the study group than in the control group (n = 8, or 4.7%; p=0.003). The result of the multivariate analysis showed that taking COCs negatively affect cervical cancer development (p=0.018; odds ratio (OR) 1.230; CI 1.064–1.423). The receiver operating characteristic analysis revealed that the use of COCs has a high predictive value for determining the risk of cervical cancer (area under the curve, AUC=0.742); the sensitivity and specificity of this predictor were 74.07% and 72.73%, respectively. In the assessment on the effect of duration of COC use on the risk of cervical cancer, the results showed that total use of COCs for over 7 years was associated with a higher risk of cervical cancer development (p=0.010; OR 1.68; CI 1.1–2.5). CONCLUSIONS: Prescribing COCs in patients with HPV infection requires a personalized approach to consider etiologic factors of cervical cancer and reduce possible carcinogenic risks.

20 March 2022 in Russian Open Medical Journal
Verified
Journal Article
Closed access
LKLidia Klyukina
Lidia Klyukina
ESElena A. Sosnova
Elena A. Sosnova
AIAnton A. Ishchenko
Anton A. Ishchenko
Mutations of the BRCA1/2 genes constitute a fundamental and independent risk factor in the genesis of both breast cancer and ovarian cancer. The specifics of the infertility treatment effect on the risk of developing cancer in carriers of mutations in the BRCA1/2 genes remain unclear and require a comprehensive investigation. In this review, we analyzed published sources on the possible relationship between the infertility treatment and the risk of ovarian and breast cancer in BRCA1/2 mutation carriers.

27 April 2022 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
LKLidia Klyukina
Lidia Klyukina
SSSosnova E.A. Sosnova
Sosnova E.A. Sosnova
IIIschenko A.A. Ischenko
Ischenko A.A. Ischenko

24 December 2021 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
LKLidia Klyukina
Lidia Klyukina
SSSosnova E.A. Sosnova
Sosnova E.A. Sosnova
IIIschenko A.A. Ischenko
Ischenko A.A. Ischenko